rectum. An aspirate of luminal fluid was collected when present.
To determine if 16S rDNA from the genus Helicobacter was present in any of the samples, a nested PCR was performed. Two positive controls were set up for each subject to account for fecal inhibition of PCR (12, 13) . One of the duplicate biopsy specimens and a 100-l aliquot of luminal fluid were spiked with approximately 10 2 and 10 3 CFU of H. muridarum (ATCC 49282), respectively. DNA was extracted from all samples by using the Puregene kit (Gentra Systems, Minneapolis, Minn.) and amplified in the first-round hot-start PCR with the bacterial primers F27 (25) and R1494 (14) on a Sprint thermal cycler (Hybaid, Ashford, Middlesex, United Kingdom). Cycling consisted of 94°C for 4 min, 30 cycles of 94°C for 15 s, 50°C for 20 s, and 72°C for 2 min, and finally 72°C for 7 min. A 1:25 dilution of the first-round product (including the negative controls) was amplified in the second round with the Helicobacter genus-specific primers H276f and H676r (19) . Cycling consisted of 94°C for 4 min, 35 cycles of 94°C for 5 s, 57°C for 5 s, and 72°C for 30 s, and finally 72°C for 2 min. The presence of the PCR product was assessed by agarose gel electrophoresis, and all positive samples were sequenced.
A total of 360 biopsy specimens (mean, 5.1 per subject; range, 0 to 6) and 56 luminal fluid aspirates were collected from the 70 subjects. Helicobacter DNA was detected in nine samples obtained from 6 of the 70 subjects: 2 controls, 2 with UC, and 2 with CD (Table 1 ). For three of the patients with positive samples, two samples were positive (two biopsy specimens for two patients and a biopsy specimen and a luminal fluid aspirate for the other), and for the remaining three, only one sample was positive (a biopsy specimen for two patients and a luminal fluid aspirate for the other). Three of the subjects with positive samples had known gastric H. pylori infection, two were of unknown status, and one was negative. This negative individual had undergone a previous Bilroth II partial gastrectomy and had documented H. pylori infection in 1995, with subsequent eradication. The other 338 samples were negative. In 68 of 70 subjects, the biopsy specimen and luminal fluid aliquot spiked with H. muridarum were positive. In the other two subjects, only the spiked luminal fluid sample was positive.
Sequencing of the PCR product from the nine positive samples revealed an identical 356-bp DNA sequence that com-pletely matched the 16S rDNA of H. pylori. This sequence differed from the corresponding sequences of H. cinaedi (AF348745) H. fennelliae (AF348746), H. heilmannii (AF058768), H. bilis (AF047843), and H. hepaticus (AF302103) by 2.5, 2.5, 3.6, 3.9, and 4.2%, respectively. There was no significant difference in the proportion of subjects with IBD who had detectable Helicobacter DNA in ileal or colonic samples compared with controls ( 2 test, P ϭ 0.32). Samples from 8.6% of the subjects in this study contained Helicobacter 16S rDNA compared with those from 33 to 60% of subjects in previously reported studies (2, 23; Linskens et al., abstract, 2000). In all of the positive samples, the resulting sequence was identical to H. pylori 16S rDNA. Although these sequence data are insufficient to state with certainty that washdown of gastric H. pylori was the source of this DNA, this conclusion would appear highly likely (21, 24) . The use of spiked control samples for each individual means that the presence of Helicobacter species, as defined by current primer sequences, in numbers greater than 10 2 per biopsy specimen and 10 4 per ml of luminal aspirate can be excluded. Previous studies have shown that a substantial layer of colonic mucus remains after bowel preparation, so that loss of mucus is unlikely to explain the negative results (18, 22) . Therefore, there does not appear to be a significant population of Helicobacter species colonizing the colonic mucus of urban Australian IBD patients or controls.
This observation is consistent with that of Bohr et al. (2) In PCR studies, problems with reaction specificity and contamination of nested assays can mislead clinicians and stimulate further research of limited value (17) . To make these studies more robust, we recommend that PCR studies reporting negative results include spiked controls from each patient and that the results of positive studies be confirmed by culture or fluorescent in situ hybridization. 
